Background The treatment of unresectable, locally advanced stage III non-small cell lung cancer (NSCLC) is concurrent chemoradiation therapy (CRT), followed by consolidation durvalumab. This study aims to evaluate the benefit of neoadjuvant osimertinib as an alternative therapy to this approach with the aim of reducing the radiation field. Methods This investigation was a nonrandomized, open-label, single-arm, phase II prospective, proof-of-concept study.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Esther
Contact Esther, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack